
---
title: '赛隆药业：注射用替加环素和注射用胸腺法新通过仿制药一致性评价'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=7826'
author: 证券时报网
comments: false
date: Fri, 15 Apr 2022 16:05:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=7826'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002898" style="color: #2f67d1;text-decoration: none;" code="002898" target="_blank">赛隆药业</a>(002898)4月15日晚间公告，公司全资子公司湖南<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002898" style="color: #2f67d1;text-decoration: none;" code="002898" target="_blank">赛隆药业</a>有限公司的注射用替加环素和注射用胸腺法新通过仿制药质量与疗效一致性评价。</p>

                  
</div>
            